Epcoritamab-bysp (Epkinly)
Epcoritamab-bysp (Epkinly) is a bispecific CD20-directed CD3 T-cell engager. This bispecific antibody binds with one arm to the tumor antigen and the other arm of the antibody binds to CD3 on the T-cell surface.
Epcoritamab-bysp is approved for the treatment of relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma and high-grade B-cell lymphoma. These indications are under the accelerated approval program for refractory hematological malignancies from the FDA. Clinical benefit and verification are necessary for continued approval of these indications.